Solifenacin/tamsulosin

Drug Profile

Solifenacin/tamsulosin

Alternative Names: EC905; Solifenacin succinate/tamsulosin hydrochloride; Tamsulosin hydrochloride/solifenacin succinate; Tamsulosin/solifenacin; Urizia; Vesomni; Volutsa

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Rovi
  • Class Antispasmodics; Quinuclidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Benign prostatic hyperplasia

Most Recent Events

  • 30 Apr 2015 No recent reports on development identified - Phase-III for Benign prostatic hyperplasia in Austria, Belarus, Belgium, France, Germany, Hungary, Italy, Poland, Russia and Slovakia (PO)
  • 11 Feb 2015 Rovi acquires the marketing rights of solifenacin/tamsulosin in Spain
  • 01 Sep 2013 Launched for Benign prostatic hyperplasia in Netherlands (PO) - first global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top